ArticlePulmonary therapy2026
Estimating the Underreporting of COVID-19 Burden in Selected Countries in Asia, Africa, the Middle East, and Latin America in the Post-pandemic Era.
Article in Pulmonary therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe true number of coronavirus disease-19 (COVID-19) cases may be highly underestimated because of reduced efforts to track cases through testing in the postpandemic era. Earlier estimates of this underreporting have varied across regions, and countries in Asia, Africa, the Middle East, and Latin America have been notably impacted. This study investigates the true burden of COVID-19 cases in 2023 and 2024 across Asia, Africa, the Middle East, and Latin America.
methodsWe conducted a retrospective analysis of national public health surveillance data from 2022 to 2024 on COVID-19 cases, hospitalizations, and deaths in Asia, Africa, the Middle East, and Latin America. Using a method developed by the US Centers for Disease Control and Prevention to estimate the burden of COVID-19 and influenza, we estimated the number of cases for 2023 and 2024 by calculating the ratio of cases to hospitalization and cases to deaths, using 2022 as the baseline. We compared the estimated and reported number of cases each year to assess the level of underreporting.
resultsThe mean ratio of estimated cases to reported cases showed a high albeit variable level of underreporting in 2023 and 2024 across regions. In 2023, the levels of underreported cases were 1295%, 319%, 560%, and 3703% in Asia, the Middle East, Latin America, and Africa, respectively. The number of estimated underreported cases generally increased in 2024 to 2326%, 1415% and 16,664% in Asia, Latin America, and Africa, respectively, but in the Middle East decreased to 87% based on hospitalization data. The trend for death data was similar.
conclusionsThe results highlight the high level of underreporting of COVID-19 cases, which has increased over time in many regions. Therefore, the true global burden of COVID-19 could be substantially higher than indicated by publicly available data. Continued COVID-19 surveillance is crucial for stabilizing public health measures such as prevention and target vaccination programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.